{
    "nct_id": "NCT04799353",
    "official_title": "A Randomized, Double-Blind, Placebo-controlled Single-Dose Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Administration of Budigalimab in Adult People Living With HIV-1 (PLWH)",
    "inclusion_criteria": "* Condition of generally good health, body mass index ≥ 18.0 to < 35.0 kg/m2.\n* Laboratory values must meet acceptable criteria.\n* Human Immunodeficiency Virus (HIV-1) infected on antiretroviral therapy (ART) for at least 12 months prior to screening and on current ART regimen for at least 8 weeks prior to screening.\n* CD4 cell count ≥ 450 cells/μL at Screening and during the 12 months prior to Screening.\n* Plasma HIV-1 RNA below the lower limit of quantification at Screening and at least 6 months prior to Screening.\n* Participants agreeing to use an effective barrier method of protection (male and/or female condom) during sexual activity from Study Day 1 through last study visit for the purposes of prevention of HIV transmission.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Participants with signs/symptoms associated with SARS-CoV-2 infection OR Current SARS-CoV-2 infection by any viral nucleic acid test completed within 7 days prior to the Day 1 dose.\n* Participants having history or ongoing diagnosis of acquired immunodeficiency syndrome (AIDS)-defining illness.\n* Participants having history of or active immunodeficiency (other than HIV).\n* Participants having active autoimmune disease or history of autoimmune disease that has required systemic treatment.\n* Prior therapy/exposure to budigalimab or any other immune checkpoint inhibitor [e.g., anti-programmed cell death protein 1(PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4].\n* Participants having clinically significant medical disorders that might expose the subjects to undue risk of harm, confound study outcomes, or prevent the subject from completing the study.\n* Participants having active or suspected malignancy or history of malignancy (other than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years.\n* Participants with history of or active tuberculosis (TB) at screening.\n* Participants having known psychiatric or substance abuse disorders that would interfere with adherence to study requirements.\n* Participants who have received immunomodulatory or immunosuppressive (including IV/orally administered [PO] steroids at any dose, but excluding steroids that are inhaled, topical or via local injection) therapy within 24 weeks prior to the first dose of study drug.",
    "miscellaneous_criteria": ""
}